DaVita Labs appoints vp and general manager

Chronic kidney disease laboratory hires Leslie Mirani

DaVita Labs, a specialist laboratory focused on chronic kidney disease, has appointed Leslie Mirani as vice president and general manager.

Mirani brings to DaVita Labs more than 25 years’ experience in commercial sales and marketing – primarily renal-focused – in the pharmaceutical industry. She previously worked for Human Genome Sciences as an immunology sales director and as vice president for Amgen’s nephrology business unit for 18 years.

DaVita Labs has 86,700ft2 dedicated to its clinical diagnostic laboratories between its two locations in Fort Lauderdale and DeLand, Florida, US.

You may also like

Ingredients

New ion chromatograph enhances water quality testing efficiency

Shimadzu’s Nexera IC combines automation and intuitive software to support reliable ion analysis and reduce laboratory workload
Manufacturing

Thermo Fisher and SHL Medical collaborate to integrate autoinjector assembly with sterile fill-finish at Ridgefield site

The duo will integrate the SHL's Molly autoinjector platform into Thermo's Ridgefield, New Jersey facility, creating an end-to-end US-based solution for drug-device combination products spanning sterile manufacturing, device assembly and commercial packaging
Manufacturing

Rentschler celebrates progress of Massachusetts site

The event recognised the site's achievements and highlighted its importance within Rentschler's global network. Upgrades on the facility began in 2019, with the site now a cutting-edge, multi-product installation
Digital

Haleon to use SAP's Business Suite to advance AI capabilities

The pair have announced a new partnership with Haleon using SAP Business Suite to advance AI capabilities across its business and deliver its everyday health products at scale
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

From lab to patient: how Fujifilm Cellular Dynamics is scaling iPSC therapies towards commercialisation

As induced pluripotent stem cell therapies move closer to commercial reality, Fujifilm Cellular Dynamics' COO Delara Motlagh explains how manufacturers are navigating the complex journey from early-phase flexibility to scalable, regulatory-ready production
Regulatory

MHRA gives guidance to phase out animal testing

The UK regulatory body is aiming to replace animal usage in science by backing developers using non-animal methods and offering early data reviews, with PETA saying innovation "must be adopted or we will be left in the dust"
You need to be a subscriber to read this article.
Click here to find out more.
Pharma 5.0

Brightseed launches AI-powered health sciences innovation platform

Life sciences AI company Brightseed has unveiled an enterprise platform connecting bioactive discovery, development and commercialisation within a unified architecture, drawing on more than a decade of research and a proprietary dataset spanning more than 11 million natural compounds
Subscribe now